Table 3.
Reduction in eNOS and/or VEGF levels with respect to PFS/OS.
| No. patients | PFS (months) | OS (months) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No. events | Median PFS (95% CI) | HR (95% CI) | P | No. events | Median OS (95% CI) | HR (95% CI) | P | ||
| CT + B | |||||||||
| Other | 23 | 19 | 8.1 (4.5–10.2) | 1.00 | 18 | 13.1 (8.2–22.7) | 1.00 | ||
| eNOS or VEGF reduction ≥ 30% | 28 | 25 | 11.9 (9.2–15.9) | 0.68 (0.40–1.16) | 0.161 | 18 | 28.8 (15.9–42.9) | 0.50 (0.27–0.91) | 0.023 |
| Other | 34 | 29 | 9.0 (6.1–10.2) | 1.00 | 25 | 14.4 (9.0–22.7) | 1.00 | ||
| eNOS and VEGF reduction ≥30% | 17 | 15 | 12.6 (9.2–22.3) | 0.59 (0.32–1.07) | 0.083 | 11 | 31.6 (21.3–49.5) | 0.38 (0.19–0.78) | 0.008 |
| CT | |||||||||
| Other | 24 | 21 | 9.1 (7.4–10.0) | 1.00 | 17 | 18.8 (14.0–28.0) | 1.00 | ||
| eNOS or VEGF reduction ≥30% | 33 | 31 | 10.3 (7.2–12.2) | 0.90 (0.54–1.50) | 0.696 | 24 | 24.3 (20.0–29.6) | 0.76 (0.43–1.34) | 0.342 |
| Other | 39 | 36 | 9.0 (7.4–9.6) | 1.00 | 27 | 20.8 (17.1–28.0) | 1.00 | ||
| eNOS and VEGF reduction ≥30% | 18 | 16 | 11.4 (8.9–15.0) | 0.79 (0.45–1.41) | 0.430 | 14 | 24.3 (15.0–30.2) | 0.89 (0.48–1.65) | 0.705 |
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; CT, chemotherapy; B, bevacizumab.